IMR Press / CEOG / Volume 28 / Issue 4 / pii/2001057

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Biochemical and body weight changes with metformin in polycystic ovary syndrome

Show Less
1 Department of Gynecology and Obstetrics, University of Istanbul, Istanbul Faculty of Medicine (Turkey)
2 Universitatsfrauenklinik, Kantompital, Basel (Switzerland)
Clin. Exp. Obstet. Gynecol. 2001, 28(4), 212–214;
Published: 10 December 2001

Objective: To evaluate the long-term effects of metformin on biochemical variables and body weight in polycystic ovary syn­drome (PCOS).

Method: Fifteen obese PCOS patients that attended the university clinic were included to this prospective study. These patients used 1,500 mg of metformin daily for 12 months. Result: We found a statistically different decrease in mean body mass index (t:4,369), (p:0.0002) at the end of the 12 months. In contrast to that there were no statistical differences in fasting serum insulin and testosterone levels. Metformin improved menstruel patterns (60% of cases) in obese PCOS patients. Conclusion: Hyperinsulinemia and androgen excess in obese nondiabetic women with PCOS are not improved by the admini­stration of metformin. Metformin treatment may have improved menstruel patterns by a mechanism independent of and unrelated to insulin sensitivity or circulating insulin concentrations.

Polycystic ovary syndrome
Body mass index
Back to top